Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
Sarah Ackroyd, Elbert S. Huang, Katherine C. Kurnit, Nita K. Lee
Topics & Concepts
MedicinePembrolizumabEndometrial cancerLenvatinibOncologyInternal medicineCohortCarboplatinCost-effectiveness analysisCost effectivenessCancerGynecologyChemotherapyImmunotherapyCisplatinThyroid cancerRisk analysis (engineering)Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis